Selected article for: "IFN subtype and immune ifn"
Author: Yang, Lei; Wang, Jianhui; Hui, Pei; Yarovinsky, Timur O.; Badeti, Saiaditya; Pham, Kien; Liu, Chen
Title: Potential role of IFN-α in COVID-19 patients and its underlying treatment options
  • Cord-id: hsnuzjug
  • Document date: 2021_5_5
    • ID: hsnuzjug
    Snippet: The coronavirus disease (COVID-19) caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly worldwide. Given that this contagious viral outbreak is still unfolding, it is urgent to understand the pathogenesis of SARS-CoV-2 infection and explore effective treatments to protect patients from developing a severe illness related to COVID-19. Recently, IFN-α has been considered a potential therapeutic strategy to treat COVID-19 disease, mainly because the innate im
    Document: The coronavirus disease (COVID-19) caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly worldwide. Given that this contagious viral outbreak is still unfolding, it is urgent to understand the pathogenesis of SARS-CoV-2 infection and explore effective treatments to protect patients from developing a severe illness related to COVID-19. Recently, IFN-α has been considered a potential therapeutic strategy to treat COVID-19 disease, mainly because the innate immune system rapidly produces IFN-α as the first line of defense to combat viral infections. However, IFN-α can also play a role in immunoregulatory effects, causing pathogenic damage and uncontrolled inflammatory responses. There are 13 human IFN-α subtypes that bind to the same receptor and induce different interferon-stimulated gene (ISG) expression, regulating various antiviral and immunoregulatory effects. The varying degrees of inflammatory regulations may raise concerns about the possible side effects to enlarge the inflammatory responses, exacerbating the severity of infection. Thus, the analysis of various IFN-α subtype induction during SARS-CoV-2 infection is necessary in exploring the mechanism of COVID-19 pathogenesis. This review summarizes the current understanding of IFN-α in the pathogenesis of respiratory virus diseases and IFN-α based clinical intervention used in SARS-CoV-2 infection and other respiratory virus diseases. Besides, new ideas in selecting suitable IFN-α subtypes or combinations as drug candidates for viral infection treatment will also be discussed. Key Points • IFN-α plays an important role in anti-viral and immunoregulatory effects in COVID-19 patients caused by SARS-CoV-2. • The uncontrolled inflammation and disease severity correlated to the diversity of IFN-α subtype induction. • Selecting suitable IFN-α subtypes or combinations as drug candidates will be beneficial for the treatment of patients with COVID-19. [Image: see text]

    Search related documents:
    Co phrase search for related documents
    • activation phosphorylation and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • activation phosphorylation and adaptor protein: 1, 2, 3, 4
    • activation phosphorylation and administration time: 1
    • activation recruitment and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8
    • activation recruitment and acute ards respiratory distress syndrome pneumonia: 1
    • activation recruitment and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • activation recruitment and adaptor molecule: 1, 2, 3
    • activation recruitment and adaptor protein: 1, 2, 3, 4, 5, 6, 7
    • activation recruitment and administration time: 1
    • activator janus kinase signal transducer and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4
    • activity inhibitor and acute ards respiratory distress syndrome: 1, 2
    • activity inhibitor and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activity inhibitor and administration time: 1
    • acute ards respiratory distress syndrome and adaptor protein: 1
    • acute ards respiratory distress syndrome and administration time: 1, 2, 3, 4, 5, 6
    • acute sars cov respiratory syndrome coronavirus and additional insight: 1, 2
    • acute sars cov respiratory syndrome coronavirus and additional insight provide: 1
    • acute sars cov respiratory syndrome coronavirus and administration time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute sars cov respiratory syndrome coronavirus and long sense: 1, 2, 3, 4, 5, 6